QQQ   277.84 (+0.68%)
AAPL   115.81 (+1.51%)
MSFT   210.33 (+1.48%)
FB   261.90 (+0.04%)
GOOGL   1,465.60 (-0.03%)
AMZN   3,148.73 (+0.12%)
TSLA   429.01 (+2.37%)
NVDA   541.22 (+2.30%)
BABA   293.98 (+6.16%)
CGC   14.32 (-1.24%)
MU   46.96 (-7.39%)
GE   6.23 (+1.80%)
AMD   81.99 (+0.27%)
T   28.51 (+0.74%)
F   6.66 (+0.91%)
ACB   4.65 (-0.64%)
GILD   63.19 (+1.76%)
NFLX   500.03 (+1.33%)
DIS   124.08 (-1.05%)
BA   165.26 (+1.01%)
BAC   24.09 (+1.35%)
QQQ   277.84 (+0.68%)
AAPL   115.81 (+1.51%)
MSFT   210.33 (+1.48%)
FB   261.90 (+0.04%)
GOOGL   1,465.60 (-0.03%)
AMZN   3,148.73 (+0.12%)
TSLA   429.01 (+2.37%)
NVDA   541.22 (+2.30%)
BABA   293.98 (+6.16%)
CGC   14.32 (-1.24%)
MU   46.96 (-7.39%)
GE   6.23 (+1.80%)
AMD   81.99 (+0.27%)
T   28.51 (+0.74%)
F   6.66 (+0.91%)
ACB   4.65 (-0.64%)
GILD   63.19 (+1.76%)
NFLX   500.03 (+1.33%)
DIS   124.08 (-1.05%)
BA   165.26 (+1.01%)
BAC   24.09 (+1.35%)
QQQ   277.84 (+0.68%)
AAPL   115.81 (+1.51%)
MSFT   210.33 (+1.48%)
FB   261.90 (+0.04%)
GOOGL   1,465.60 (-0.03%)
AMZN   3,148.73 (+0.12%)
TSLA   429.01 (+2.37%)
NVDA   541.22 (+2.30%)
BABA   293.98 (+6.16%)
CGC   14.32 (-1.24%)
MU   46.96 (-7.39%)
GE   6.23 (+1.80%)
AMD   81.99 (+0.27%)
T   28.51 (+0.74%)
F   6.66 (+0.91%)
ACB   4.65 (-0.64%)
GILD   63.19 (+1.76%)
NFLX   500.03 (+1.33%)
DIS   124.08 (-1.05%)
BA   165.26 (+1.01%)
BAC   24.09 (+1.35%)
QQQ   277.84 (+0.68%)
AAPL   115.81 (+1.51%)
MSFT   210.33 (+1.48%)
FB   261.90 (+0.04%)
GOOGL   1,465.60 (-0.03%)
AMZN   3,148.73 (+0.12%)
TSLA   429.01 (+2.37%)
NVDA   541.22 (+2.30%)
BABA   293.98 (+6.16%)
CGC   14.32 (-1.24%)
MU   46.96 (-7.39%)
GE   6.23 (+1.80%)
AMD   81.99 (+0.27%)
T   28.51 (+0.74%)
F   6.66 (+0.91%)
ACB   4.65 (-0.64%)
GILD   63.19 (+1.76%)
NFLX   500.03 (+1.33%)
DIS   124.08 (-1.05%)
BA   165.26 (+1.01%)
BAC   24.09 (+1.35%)
Log in
NASDAQ:BCLI

Brainstorm Cell Therapeutics Stock Forecast, Price & News

$16.92
+0.73 (+4.51 %)
(As of 09/30/2020 12:00 AM ET)
Add
Compare
Today's Range
$16.21
Now: $16.92
$17.08
50-Day Range
$11.74
MA: $13.51
$16.19
52-Week Range
$3.58
Now: $16.92
$17.20
Volume1.02 million shs
Average Volume619,857 shs
Market Capitalization$533.45 million
P/E RatioN/A
Dividend YieldN/A
Beta1.08
Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of central nervous system (CNS) adult stem cell therapies designed to address the unmet medical needs of patients with debilitating neurodegenerative diseases. The company holds rights to develop and commercialize its NurOwn technology that utilizes a patient's own cells, which are engineered outside the body, to produce and secrete factors known to promote neuronal survival. It is developing NurOwn for various neurodegenerative diseases, including its lead indication, which is in Phase III clinical trial for the treatment of amyotrophic lateral sclerosis, as well as in preclinical trial for the treatment of multiple sclerosis, Parkinson's disease, Huntington's disease, and autism spectrum disorder. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004 to reflect its new line of business in the development of novel cell therapies for neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was founded in 2000 and is headquartered in New York, New York.
Read More
Brainstorm Cell Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.5Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.23 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:BCLI
CUSIPN/A
Phone201-488-0460

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value($0.54) per share

Profitability

Net Income$-23,250,000.00

Miscellaneous

Employees31
Market Cap$533.45 million
Next Earnings Date11/12/2020 (Estimated)
OptionableOptionable
$16.92
+0.73 (+4.51 %)
(As of 09/30/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive BCLI News and Ratings via Email

Sign-up to receive the latest news and ratings for BCLI and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Brainstorm Cell Therapeutics (NASDAQ:BCLI) Frequently Asked Questions

How has Brainstorm Cell Therapeutics' stock price been impacted by COVID-19?

Brainstorm Cell Therapeutics' stock was trading at $6.68 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, BCLI stock has increased by 153.3% and is now trading at $16.92.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Brainstorm Cell Therapeutics?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Brainstorm Cell Therapeutics in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Brainstorm Cell Therapeutics
.

When is Brainstorm Cell Therapeutics' next earnings date?

Brainstorm Cell Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, November 12th 2020.
View our earnings forecast for Brainstorm Cell Therapeutics
.

How were Brainstorm Cell Therapeutics' earnings last quarter?

Brainstorm Cell Therapeutics Inc (NASDAQ:BCLI) announced its earnings results on Wednesday, August, 5th. The biotechnology company reported ($0.25) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.26) by $0.01.
View Brainstorm Cell Therapeutics' earnings history
.

What price target have analysts set for BCLI?

1 brokers have issued 12-month price targets for Brainstorm Cell Therapeutics' stock. Their forecasts range from $20.00 to $20.00. On average, they anticipate Brainstorm Cell Therapeutics' stock price to reach $20.00 in the next year. This suggests a possible upside of 18.2% from the stock's current price.
View analysts' price targets for Brainstorm Cell Therapeutics
.

Who are some of Brainstorm Cell Therapeutics' key competitors?

What other stocks do shareholders of Brainstorm Cell Therapeutics own?

Who are Brainstorm Cell Therapeutics' key executives?

Brainstorm Cell Therapeutics' management team includes the following people:
  • Dr. Irit Arbel, Founder & Chairperson (Age 59)
  • Mr. Chaim Lebovits, Pres & CEO (Age 48)
  • Mr. Eyal Rubin, CFO & Treasurer (Age 43)
  • Dr. Ralph Z. Kern, COO & Chief Medical Officer (Age 61)
  • Mr. Uri Yablonka, Exec. VP, Chief Bus. Officer & Director (Age 42)

What is Brainstorm Cell Therapeutics' stock symbol?

Brainstorm Cell Therapeutics trades on the NASDAQ under the ticker symbol "BCLI."

How do I buy shares of Brainstorm Cell Therapeutics?

Shares of BCLI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Brainstorm Cell Therapeutics' stock price today?

One share of BCLI stock can currently be purchased for approximately $16.92.

How big of a company is Brainstorm Cell Therapeutics?

Brainstorm Cell Therapeutics has a market capitalization of $533.45 million. The biotechnology company earns $-23,250,000.00 in net income (profit) each year or ($1.06) on an earnings per share basis. Brainstorm Cell Therapeutics employs 31 workers across the globe.

What is Brainstorm Cell Therapeutics' official website?

The official website for Brainstorm Cell Therapeutics is www.brainstorm-cell.com.

How can I contact Brainstorm Cell Therapeutics?

Brainstorm Cell Therapeutics' mailing address is 1325 AVENUE OF AMERICAS 28TH FLOOR, NEW YORK NY, 10019. The biotechnology company can be reached via phone at 201-488-0460 or via email at [email protected]

This page was last updated on 9/30/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.